Are Anti-β2 Glycoprotein 1 Antibodies Associated with Placenta-Mediated Pregnancy Complications? A Nested Case–Control Study

Abstract Background While anti-β2 glycoprotein 1 (anti-β2GP1) antibody positivity is included in the diagnostic criteria for antiphospholipid syndrome (APS), the association between anti-β2GP1 and the obstetrical complications of APS has been inconsistently reported and remains unclear. Objective We completed a case–control study nested within the Canadian Ottawa and Kingston (OaK) Birth Cohort to evaluate the association between anti-β2GP1 antibody positivity and placenta-mediated pregnancy complications. Study Design Five hundred cases were randomly selected among pregnant women who experienced any of the following independently adjudicated placenta-mediated pregnancy complications: preeclampsia, placental abruption, late pregnancy loss (≥ 12 weeks' gestation), and birth of a small-for-gestational age (SGA) infant < 10th percentile. Five hundred pregnant women without any placenta-mediated pregnancy complications were selected as controls. Stored blood samples were analyzed for the presence of anti-β2GP1 antibodies by enzyme-linked immunosorbent assay. Results Anti-β2GP1 immunoglobulin G (IgG) and/or immunoglobulin M (IgM) antibodies in titers ≥ 20 G/M units (> 99th percentile) were present in 24 of 497 (4.8%) of controls and 33 of 503 (6.6%) of cases. There was no significant difference between cases and controls for the composite outcome of any placenta-mediated pregnancy complications (odds ratio, 1.38, 95% confidence interval [CI], 0.8–2.37, p = 0.25). Conclusion Our results call into question the association between anti-β2GP1 antibodies and placenta-mediated pregnancy complications, with further research needed.

[1]  Mimi Y. Kim,et al.  Brief Report: Changes in Antiphospholipid Antibody Titers During Pregnancy: Effects on Pregnancy Outcomes , 2016, Arthritis & rheumatology.

[2]  J. Gris,et al.  Antiphospholipid antibodies and the risk of severe and non‐severe pre‐eclampsia: the NOHA case‐control study , 2016, Journal of thrombosis and haemostasis : JTH.

[3]  Mimi Y. Kim,et al.  Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results , 2016, Lupus Science & Medicine.

[4]  K. McCrae,et al.  The antiphospholipid syndrome: still an enigma. , 2015, Hematology. American Society of Hematology. Education Program.

[5]  G. Espinosa,et al.  The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 247 consecutive cases. , 2015, Autoimmunity reviews.

[6]  M. Rodger,et al.  Is thrombophilia associated with placenta‐mediated pregnancy complications? A prospective cohort study , 2014, Journal of thrombosis and haemostasis : JTH.

[7]  J. Gris,et al.  Comparative incidence of pregnancy outcomes in treated obstetric antiphospholipid syndrome: the NOH-APS observational study. , 2014, Blood.

[8]  C. Parker,et al.  Antiphospholipid Antibodies in Stillbirth , 2013, Obstetrics and gynecology.

[9]  S. Krilis,et al.  The pathogenesis of the antiphospholipid syndrome. , 2013, The New England journal of medicine.

[10]  Mimi Y. Kim,et al.  Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. , 2012, Arthritis and rheumatism.

[11]  J. Alijotas-Reig,et al.  Prevalence and clinical usefulness of antiphospholipid and anticofactor antibodies in different Spanish preeclampsia subsets , 2012, Lupus.

[12]  D. Veenstra,et al.  VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[13]  M. Rodger,et al.  The Ottawa and Kingston (OaK) Birth Cohort: development and achievements. , 2011, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.

[14]  A. Tincani,et al.  Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study. , 2011, Rheumatology.

[15]  M. Rodger,et al.  The association between antiphospholipid antibodies and placenta mediated complications: a systematic review and meta-analysis. , 2011, Thrombosis research.

[16]  P. D. de Groot,et al.  The association between circulating antibodies against domain I of beta2‐glycoprotein I and thrombosis: an international multicenter study , 2009, Journal of thrombosis and haemostasis : JTH.

[17]  T. Koike,et al.  Antiphospholipid antibodies increase the risk of pregnancy-induced hypertension and adverse pregnancy outcomes. , 2009, Journal of reproductive immunology.

[18]  K. Ghosh,et al.  A comprehensive screening analysis of antiphospholipid antibodies in Indian women with fetal loss. , 2008, European journal of obstetrics, gynecology, and reproductive biology.

[19]  Chan Jun-mi,et al.  International Consensus Statement on an Update of the Classification Criteria for Definite Antiphospholipid Syndrome(APS) , 2008 .

[20]  G. Guyatt,et al.  Physicians Evidence-Based Clinical Practice Development : American College of Chest Thrombolytic Therapy Guideline Methodology for Antithrombotic and , 2008 .

[21]  D. Kirchhofer,et al.  Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. , 2007, Blood.

[22]  M. Paidas,et al.  Adverse pregnancy outcome, the uteroplacental interface, and preventive strategies. , 2007, Seminars in perinatology.

[23]  K. Ward,et al.  Anticardiolipin and anti-β2-glycoprotein-I antibodies in preeclampsia , 2003 .

[24]  D. Alarcón-Segovia,et al.  Anticardiolipin and anti-beta2-glycoprotein-I antibodies in hypertensive disorders of pregnancy. , 2002, Archives of medical research.

[25]  R W Platt,et al.  A new and improved population-based Canadian reference for birth weight for gestational age. , 2001, Pediatrics.

[26]  R. Silver,et al.  Anti–β2-glycoprotein I antibodies in women with recurrent spontaneous abortion, unexplained fetal death, and antiphospholipid syndrome , 1999 .

[27]  R. Silver,et al.  Anti-beta2-glycoprotein I antibodies in women with recurrent spontaneous abortion, unexplained fetal death, and antiphospholipid syndrome. , 1999, American journal of obstetrics and gynecology.

[28]  E. Matsuura,et al.  beta 2-Glycoprotein I-dependent anticardiolipin antibodies as a predictor of adverse pregnancy outcomes in healthy pregnant women. , 1996, Human reproduction.

[29]  E. Matsuura,et al.  beta 2-Glycoprotein I-dependent anticardiolipin antibodies as a predictor of adverse pregnancy outcomes in healthy pregnant women. , 1996, Human reproduction.

[30]  B. Roussel,et al.  Anti-beta 2-glycoprotein I antibodies. , 1995, Clinical reviews in allergy & immunology.